Valuation: Profound Medical Corp.

Market Cap 377M 269M 234M 218M 200M 25.67B 383M 2.56B 1.01B 12.78B 1.01B 988M 42.85B P/E 2026 *
-8.89x
P/E 2027 * -9.99x
Enterprise Value 377M 269M 234M 218M 200M 25.67B 383M 2.56B 1.01B 12.78B 1.01B 988M 42.85B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 6.15x
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
1 day+1.17%
1 week+0.97%
1 month+6.46%
3 months+10.54%
6 months-2.26%
Current year-3.62%
1 week 9.85
Extreme 9.85
10.66
1 month 9.31
Extreme 9.31
11.2
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
22.63
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 14/08/2016
President 44 06/11/2024
Director of Finance/CFO 58 02/03/2022
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 13/06/2018
Director/Board Member 79 13/06/2018
Date Insider Type Main position Quantity % Market Cap.
24/06/26 Option

Director

2,016 0.0055%
17/06/26 Option

Chairperson

11,618 0.0320%
24/12/25 Buy

Executive/Senior Manager

13,908 0.0461%
Change 5-day change 1-year change 3-year change Capi.($)
+1.17%+0.97%+33.42%-24.07% 269M
-0.43%+1.06%+24.03%+3.71% 212B
-0.61%+1.82%-1.07%-24.39% 137B
+0.10%+4.69%-26.86%+12.57% 125B
+1.59%+5.60%-55.67%-7.68% 69.46B
-0.98%+4.16%+8.50%+7.08% 49.56B
+5.85%+7.82%-17.08%-20.95% 47.2B
-0.25%-0.14%+21.91%+8.35% 39.08B
-0.79%+0.70%+29.97%+29.32% 37.05B
+0.00%+5.67%+116.67%+8.20% 30.97B
Average +0.67%+2.97%+13.38%-0.79% 74.78B
Weighted average by Cap. +0.41%+2.80%+3.93%-0.67%

Financials

2026 *2027 *
Net sales 36.23M 25.82M 22.45M 20.89M 19.18M 2.47B 36.79M 246M 96.66M 1.23B 96.98M 94.85M 4.12B 61.34M 43.72M 38.01M 35.38M 32.48M 4.17B 62.29M 417M 164M 2.08B 164M 161M 6.97B
Net income -43.53M -31.03M -26.98M -25.11M -23.05M -2.96B -44.21M -296M -116M -1.47B -117M -114M -4.95B -41.11M -29.3M -25.47M -23.71M -21.77M -2.8B -41.74M -279M -110M -1.39B -110M -108M -4.67B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
31/07/26 CA$10.38 +1.17% 8,858
30/07/26 CA$10.26 +0.20% 5,384
29/07/26 CA$10.24 -0.29% 25,922
28/07/26 CA$10.27 -1.63% 9,762
27/07/26 CA$10.44 +1.56% 45,080
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.38
Average target price
-

Quarterly revenue - Rate of surprise